(Total Views: 600)
Posted On: 03/02/2022 7:33:56 AM
Post# of 153907
Re: KenChowder #119370
Just because somebody does not agree to your erroneous logic, does not mean he is a basher, shorter or whatever.
Just because we get mentioned (with wrong spelling) with a bunch of other drugs in a scientific paper creates not an argument for or against the efficacy of Leronlimab. Are you going to FDA and show them that in this paper Leronlimab was mentioned in a sentence with the phrases "in some cases" and "severe COVID-19 manifestations". This is your argument or proof of efficacy?
The only valid argument for efficacy is the data of a trial which we have now in brazil.
We had our first chance with CD12 which we blew, because of FDA (4 doses issue) and our own trial design/ inexperience (mixture of severe and critical in one trial, age distribution, ...).
Quote:
For instance, inhibition of the CCR5-CCL4 axis by Leronlima (anti-CCR5 monoclonal antibody) [116], or the blockade of cytokine signaling by Tocilizumab (anti-IL-6R) [117], Adalimumab (anti-TNF-α) [118], or Anakinra (anti-IL1R) [119] have been shown to ameliorate, in some cases, severe COVID-19 manifestations.
Just because we get mentioned (with wrong spelling) with a bunch of other drugs in a scientific paper creates not an argument for or against the efficacy of Leronlimab. Are you going to FDA and show them that in this paper Leronlimab was mentioned in a sentence with the phrases "in some cases" and "severe COVID-19 manifestations". This is your argument or proof of efficacy?
The only valid argument for efficacy is the data of a trial which we have now in brazil.
We had our first chance with CD12 which we blew, because of FDA (4 doses issue) and our own trial design/ inexperience (mixture of severe and critical in one trial, age distribution, ...).
(5)
(2)
